American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2026
Effect of therapeutic plasma exchange on the anti-factor Xa activity of enoxaparin: A case report.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hellwig Thaddaus, Jansma Vant Hul Bri, Schaar Michaela, Shehzad Dawood, Ahmed Mamoon
Аннотация
PURPOSE: A case is reported in which the anti-factor Xa activity of enoxaparin was measured during therapeutic plasma exchange (TPE).
SUMMARY: A 52-year-old male underwent TPE for antineutrophil cytoplasmic antibody-associated vasculitis while receiving therapeutic enoxaparin. Enoxaparin anti-factor Xa levels were measured before and immediately after TPE sessions as well as outside TPE sessions. The calculated enoxaparin half-life during TPE was 0.897 hours, whereas the calculated half-life outside TPE was 5.26 hours, demonstrating that the half-life of enoxaparin is dramatically shortened during TPE.
CONCLUSION: Enoxaparin's anti-factor Xa activity should be monitored and dosing schedules should be adjusted to ensure therapeutic enoxaparin levels in all patients receiving TPE.
SUMMARY: A 52-year-old male underwent TPE for antineutrophil cytoplasmic antibody-associated vasculitis while receiving therapeutic enoxaparin. Enoxaparin anti-factor Xa levels were measured before and immediately after TPE sessions as well as outside TPE sessions. The calculated enoxaparin half-life during TPE was 0.897 hours, whereas the calculated half-life outside TPE was 5.26 hours, demonstrating that the half-life of enoxaparin is dramatically shortened during TPE.
CONCLUSION: Enoxaparin's anti-factor Xa activity should be monitored and dosing schedules should be adjusted to ensure therapeutic enoxaparin levels in all patients receiving TPE.